A formulation comprises one or more of a first group comprising any acetylcholine precursors, co-factors, co-enzymes and derivatives thereof and any substance that makes the body produce or increase the levels or enhance the action of acetylcholine, such as N-acetyl carnitine, together with one or more of a second group comprising D-ribose and precursors, co-factors, co-enzymes and derivatives of ATP and any substance that makes the body produce or increase the levels or enhance the action of ATP. The formulation also comprises one or more of a third group comprising phenylalanines and precursors, co-factors, co-enzymes and derivatives of catecholamine, and any substance that makes the body produce or increase the levels of or enhance the action of catecholamine. The formulation is for use in the treatment of one or more of a fourth group comprising chronic fatigue syndrome (CFS), chronic fatigue (e.g. due to MS), fibromyalgia, depression, anxiety, severe exhaustion (possibly chronic), obesity, overweight (including that due to chronic fatigue), severe fatigue not due to anoxia, impaired concentration and/or focus, learning difficulties, cognitive deficits, attention deficiency hyperactivity disorder (ADHD), dementia, memory loss, the motor neuron group of diseases.
